Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)
Source: View publication →
In patients with locally advanced rectal cancer, short-term radiotherapy followed by neoadjuvant chemotherapy (total neoadjuvant therapy) was non-inferior to standard long-term chemoradiotherapy for 3-year disease-free survival and resulted in significantly improved 3-year overall survival.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STELLAR trial provides robust evidence that a Total Neoadjuvant Therapy (TNT) approach utilizing short-course radiotherapy and upfront chemotherapy is a highly efficacious alternative to standard long-course chemoradiotherapy for locally advanced rectal cancer. The statistically significant 11.4% absolute improvement in 3-year overall survival, despite greater but manageable preoperative toxicity, strongly supports TNT as a standard-of-care option for this patient population, corroborating findings from similar global trials like RAPIDO.
Historical Context
Historically, the standard of care for locally advanced rectal cancer consisted of long-course concurrent chemoradiotherapy (CRT) followed by total mesorectal excision (TME) and postoperative adjuvant chemotherapy. However, adherence to adjuvant chemotherapy is notoriously poor (only approximately 50% complete it) due to surgical morbidity, resulting in suboptimal systemic control and high rates of distant metastasis. The Total Neoadjuvant Therapy (TNT) paradigm emerged to address this by shifting systemic chemotherapy to the preoperative setting. The STELLAR trial was designed to evaluate whether neoadjuvant chemotherapy plus short-term radiotherapy could improve compliance and efficacy compared to standard CRT. STELLAR successfully confirmed the non-inferiority of short-course radiation followed by neoadjuvant chemotherapy for disease-free survival, and importantly showed an early overall survival benefit in a Chinese population.
Guided Discussion
High-yield insights from every perspective
What is the radiobiologic rationale behind using short-course radiotherapy (5 Gy x 5 fractions) versus long-course chemoradiation, and why is neoadjuvant therapy generally preferred over adjuvant therapy in locally advanced rectal cancer?
Key Response
This addresses foundational concepts: short-course RT leverages a higher dose per fraction relying on the alpha/beta ratio of rectal cancer to achieve similar tumor kill with shorter treatment time. Neoadjuvant therapy is preferred due to better compliance, downstaging of the tumor facilitating sphincter-sparing surgery, and lower toxicity compared to post-operative radiation in a hypoxic, scarred surgical bed.
When managing a patient with locally advanced rectal cancer, how does adopting the Total Neoadjuvant Therapy (TNT) approach from the STELLAR trial alter the expected clinical workflow, surgical timing, and toxicity monitoring compared to standard long-course chemoradiotherapy?
Key Response
Residents must understand that TNT shifts systemic chemotherapy entirely to the pre-operative setting. This improves chemotherapy compliance and tackles micrometastases early but requires careful coordination, delaying Total Mesorectal Excision (TME) surgery until after completion of both radiation and several cycles of chemotherapy, while shifting the toxicity burden to the pre-operative phase.
How do the patient inclusion criteria and choice of radiation backbone in the STELLAR trial compare to those of the RAPIDO and PRODIGE-23 trials, and how do these differences influence your selection of a TNT regimen for a high-risk patient?
Key Response
Fellows need to synthesize major TNT trials. STELLAR and RAPIDO used short-course RT followed by chemotherapy, whereas PRODIGE-23 used FOLFIRINOX followed by long-course CRT. Understanding the nuances of these regimens, such as patient risk stratification (e.g., cT4 or involved mesorectal fascia) and differences in locoregional recurrence rates, is essential for personalized oncology practice.
Given that the STELLAR trial demonstrated an overall survival benefit at 3 years for short-course TNT, but the recent RAPIDO trial update raised concerns about increased locoregional recurrence with a similar regimen, how do you balance these conflicting signals when counseling a fit patient with distal rectal cancer?
Key Response
Attendings must navigate conflicting long-term data. While STELLAR's OS benefit is compelling, the RAPIDO update reminds clinicians of the potential trade-offs in local control. Practice-changing insights require weighing systemic control against locoregional risks, often necessitating shared decision-making based on tumor height, baseline sphincter function, and patient priorities.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STELLAR trial was powered as a non-inferiority study for 3-year disease-free survival but claimed a statistically significant superiority in its secondary endpoint of overall survival. What are the methodological and alpha-spending concerns with this conclusion, and how might it affect the generalizability of the results?
Key Response
This questions expert-level statistical design. Claiming superiority on a secondary endpoint without a pre-specified hierarchical testing plan or alpha control can lead to inflated Type I error. PhD researchers must recognize this limitation when evaluating the robustness of the OS benefit and designing future confirmatory trials.
As a peer reviewer, what specific data regarding the quality of total mesorectal excision (TME) surgery, consistency of MRI staging across centers, and adherence to adjuvant chemotherapy in the control arm would you demand to rule out confounders driving the experimental arm's OS benefit?
Key Response
Editors must look for asymmetric trial execution. A known flaw in historical rectal cancer trials is poor compliance with post-operative chemotherapy in the control arm. If the control arm had low adherence, or if TME quality varied, the TNT arm might appear artificially superior, threatening the internal validity of the study's conclusions.
Does the evidence from the STELLAR trial, combined with existing data from RAPIDO, warrant updating NCCN and ESMO guidelines to universally recommend short-course Total Neoadjuvant Therapy as the preferred Category 1 standard over conventional chemoradiotherapy for all locally advanced rectal cancers?
Key Response
Guideline committees evaluate whether new evidence justifies a universal shift. Current NCCN guidelines list TNT as a preferred option for high-risk LARC. STELLAR strengthens the Category 1 evidence for short-course TNT, but committees must debate if the evidence is strong enough to discard long-course CRT entirely or if it should remain an option for specific subsets, such as distal tumors requiring maximum downsizing.
Clinical Landscape
Noteworthy Related Trials
Polish II Trial
Tested
Short-course radiotherapy followed by FOLFOX4 consolidation
Population
Patients with fixed cT3 or cT4 locally advanced rectal cancer
Comparator
Standard long-course chemoradiotherapy
Endpoint
Overall survival
RAPIDO Trial
Tested
Short-course radiotherapy followed by CAPOX or FOLFOX
Population
Patients with high-risk locally advanced rectal cancer
Comparator
Standard long-course chemoradiotherapy
Endpoint
Disease-related treatment failure at 3 years
PRODIGE 23 Trial
Tested
Neoadjuvant FOLFIRINOX followed by standard chemoradiotherapy
Population
Patients with locally advanced rectal cancer
Comparator
Standard long-course chemoradiotherapy
Endpoint
Disease-free survival at 3 years
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis